2-Acetamido-5-mercapto-1,3,4-thiadiazole | CAS:32873-56-6

We serve 2-Acetamido-5-mercapto-1,3,4-thiadiazole CAS:32873-56-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Acetamido-5-mercapto-1,3,4-thiadiazole

Chemical Name:2-Acetamido-5-mercapto-1,3,4-thiadiazole
CAS.NO:32873-56-6
Synonyms:2-Acetylamino-5-mercapto-1,3,4-thiadiazole
Molecular Formula:C4H5N3OS2
Molecular Weight:175.23200
 
Physical and Chemical Properties:
Density:1.71
Index of Refraction:1.794
 
Specification:
Appearance:White to pale yellow solid
Purity(HPLC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:For the synthesis of Acetazolamide



Contact us for information like 2-Acetamido-5-mercapto-1,3,4-thiadiazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Acetylamino-5-mercapto-1,3,4-thiadiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Acetamido-5-mercapto-1,3,4-thiadiazole Use and application,2-Acetamido-5-mercapto-1,3,4-thiadiazole technical grade,usp/ep/jp grade.


Related News: New Zealand citizens and permanent residents and their immediate family members will still be able to enter — but must self-isolate for 14 days after arriving back into the country.4-(methylamino)-3-nitrobenzoyl chloride manufacturer New Zealand citizens and permanent residents and their immediate family members will still be able to enter — but must self-isolate for 14 days after arriving back into the country.1,4-Phenylene diisocyanate supplier A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.5-Fluoro-2-nitrobenzoic acid vendor A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.